Drug Name: Amvuttra
Active Ingredient: vutrisiran
Indications: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Approval Date: 6/13/2022
Company: Alnylam Pharmaceuticals, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf